Advaxis Announces Updated Positive Clinical Data in Ongoing Phase 1/2 ADXS-503 Trial in NSCLC at I/O 360° Conference

Stock Information for Advaxis Inc.

Loading

Please wait while we load your information from QuoteMedia.